To,
The Members,
Checkpoint Trends Limited
Formerly known as Rubra Medicaments Limited
Your Directors' have pleasure in presenting Annual Report together with the Audited Accounts of the Company for the year ended 31st March, 2024.
1. FINANCIAL RESULTS
Your Company financial performance during the year 2023-24 is summarized below:
(Rs. In Thousands)
Particulars
Income from Operations
Other Income
Total Income
Less: Expenses
Profit/(Loss) Before Extraordinary Items and Tax
Less: Extraordinary Items
Profit/(Loss) Before Tax
Less: Taxation
Profit/(Loss) After Tax
EPS (in Rs.)
2. FINANCIAL SUMMARY
The Company earned income from operation of Rs. 11309.35 (in thousands) during the FY 2023-24, as compared to the income from operation of Rs. 11617.79 (in thousands) earned in the previous FY 2022-23. The Company's Net Profit for the Financial Year ended March 31, 2024 stood at Rs. 302.09 (in thousands) as against a Net loss of Rs. Rs. 785.51 (in thousands) in the previous year.
3. CHANGE IN NAME OF THE COMPANY
During the financial year under review, there is no change in the name of the Company.
4. CHANGE IN NATURE OF BUSINESS
During the financial year under review, there is no change in the nature of business of the Company.
5. TRANSFER TO RESERVES
No amount has been transferred to Reserves during the year under review.
6. CHANGES IN SHARE CAPITAL
The Authorised Share Capital of the Company is Rs.8,20,00,000/- divided into 82,00,000 equity shares of Rs. 10/- each and the paid-up share capital of the Company is Rs.5,46,83,000/- divided into 54,68,300 equity shares of Rs. 10/- each.
The Company has not issued any kind of shares or securities during the year under review.
7. DIVIDEND
The Board of Directors expressed their inability to recommend any dividend on equity shares for the year ended March 31, 2024.
8. PUBLIC DEPOSITS
During the year, the Company has not accepted any deposits from public nor during the previous financial year.
9. BUY-BACK / SWEAT EQUITY / BONUS SHARES
The Company has neither bought back its shares nor has issued any sweat equity or Bonus shares during the year under review.
10. EMPLOYEES STOCK OPTION PLAN
The Company has not provided any Stock Option Scheme to the Employees.
11. ISSUE OF DEBENTURES, BONDS OR ANY NON-CONVERTIBLE SECURITIES
The Company has not issued any debenture, bonds or non-convertible securities.
12. STATUTORY AUDITORS
The Members had appointed M/s. DD & Company (erstwhile M/s. Dinesh H. Agarwal & Company)., Chartered Accountants, as Statutory Auditor of the Company at the Annual General Meeting held on September 29, 2018 and September 30, 2021 for a period of five years in aggregate from FY 2018-19 to FY 2022-2023.
The term of Statutory Auditor will end at the ensuing Annual General Meeting ("AGM") of the Company and the Company is required to appoint new Statutory Auditors.
Pursuant to section 139 of the Companies Act, 2013 the Board in its meeting held on August 30, 2023 has recommended the appointment of M/s. L K Ajmera & Associates Chartered Accountants as new Statutory Auditor of the company to hold office for a period of five (5) financial years (for FY 2023-2024 till FY 2027-2028), i.e from conclusion of this Annual General Meeting till conclusion of Annual General Meeting to be held in the year 2028, at a remuneration to be determined by the Board of Directors and Auditors.
13. INTERNAL AUDITOR
In the Board Meeting held on August 30, 2023, Ms. Ankita Agawane, Internal Auditor of the company had resigned and the Board appointed new Internal Auditor Mr. Arun Mulya for a period of three years from FY 2023-2024 to FY 2025-2026.
14. STATUTORY AUDIT REPORT
The Auditors' Report on the financial statement for the current year is self-explanatory, therefore does not require any further explanation. The Company has already submitted declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 to the Stock Exchange(s).
15. COST AUDITOR REPORT AND COST RECORD
Appointment of Cost Auditor and maintenance of cost records is not applicable to the company.
16. SECRETARIAL AUDITOR AND SECRETARIAL AUDIT REPORT
M/s. Maithili Nandedkar & Associates, Practicing Company Secretaries, appointed as Secretarial Auditor in the Board Meeting held on held on August 12, 2021 to conduct the Secretarial Audit for the 3 (Three) financial years FY 2021-22 till FY 2023-24. Later on, M/s. Maithili Nandedkar & Associates changed their firm name to M/s. MNB & Co. LLP.
Therefore, M/s. MNB & Co. LLP, Practising Company Secretaries are the secretarial auditor for the financial year 2022-2023 and 2023-2024.
Further, the Board of Directors in their meeting held on May 25, 2024 have reappointed M/s. MNB & Co. LLP, Practising Company Secretaries for a further period of 3 years i.e. F.Y. 2024-2025 upto F.Y 2026-2027.
The Secretarial Audit Report for the Financial Year 2023-2024 forms part of the Annual Report. The Secretarial Auditors' Report presented to the Members for the year under review is qualified and is annexed to this Report.
The Secretarial Audit report for the current year is self-explanatory, therefore does not require any further explanation and listing fees has not paid due to financial crises faced by the company.
17. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12) OF SECTION 143
There are no frauds reported by the Statutory Auditors of the Company under Section 143 (12).
18. DIRECTORS AND KEY MANAGERIAL PERSONNEL
In accordance with the Companies Act, none of the Directors are liable to retire by rotation at the ensuing Annual General Meeting.
Ms. Komal Behl, Company Secretary, has tendered her resignation effective January 24, 2024. As on date, the Company does not have a Company Secretary.
Ms. Abha Rajesh Kapoor (DIN: 02799429) was re-appointed as Whole-Time Director of the Company for further period of 3 years w.e.f. June 14, 2023 till June 13, 2026
Subsequent to year under review, Mr. Sunil Khandelwal has been ceased to be a Director of the Company due to expiry of his tenure.
Also, Mr. Gopal Kumar Sahu has been re-appointed as Independent Director of the Company for a period of 5 years subject to the approval of the shareholders in the ensuing General Meeting of the Company.
Disclosure Requirement
Name of the Director
Date of appointment
Term of Appointment
Disclosure of relationship between
Directors inter-se
Declaration
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board along with listed entities from which the person has resigned in the past three years
Nature of expertise in specific functional areas
Brief profile
She is not related to any other Director of the Company and is also not a Director in any other listed company. She or her relatives do not hold any shares in the Company.
reason for change viz. appointment, re-
appointment, resignation, removal, death or otherwise;
date of appointment/re appointment/cessation (as applicable) & term of appointment/re-appointment;
His present tenure as Whole-time Director will conclude on June 10, 2024.
Terms of Re-Appointment: For the period of five years from the date of appointment subject to shareholders approval.
Brief profile (in case of appointment)
Mr. Gopal Sahu aged 28 years, is a graduate having an experience of over eight years in general trading activities. He is not related to any other Director of the Company and is also not a director in any other listed company. He or his relatives do not hold any shares in the Company.
disclosure of relationships between directors (in case of appointment of a director).
Mr. Sunil Ramesh Khandalwal is ceased to be a director due to expiry of term and not being reappointed.
appointment, resignation, lemuvul, death ui
otherwise;
date of appointment/re- appointment/cessation (as applicable) & term of appointment/re-appointment;
19. ANNUAL RETURN
The Annual Return for the financial year ended March 31, 2024 along with Notice of AGM is being uploaded on the website of the Company. The web link for the same is as under: https://www.rubramed.com/extract-annual-return.html
20. DETAILS OF SUBSIDIARIES/ASSOCIATES/JOINT VENTURES, IF ANY:
As on March 31, 2024, the Company does not have any subsidiary, associate or joint venture.
21. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE EARNINGS AND OUTGO
The information pertaining to Conservation of Energy, Technology Absorption and Foreign Exchange earnings and outgo as required under section 134(3)(m) of the Companies Act, 2013 read with rule 8(3) of the Companies (Accounts) Rules, 2014 is annexed to this report as Annexure II.
22. VIGIL MEGHANISM
The Company has established a Vigil Mechanism that enables the Directors and Employees to report genuine concerns. The Vigil Mechanism provides for
(a) adequate safeguards against victimization of persons who use the Vigil Mechanism; and
(b) direct access to the Chairperson of the Audit Committee of the Board of Directors of the Company in appropriate or exceptional cases.
The web link for the policy is as under:
https://www.rubramed.com/policies/Vigil-Mechanism-Policy.pdf
23. CORPORATE SOCIAL RESPONSIBILITY
The provisions of Corporate Social Responsibility are not applicable to the Company as it does not fall within the purview of Section 135(1) of the Companies Act, 2013.
24. RELATED PARTY TRANSACTIONS
There were no contracts or arrangements entered into by the Company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013. The related party transactions as per IND AS 24 are given in the notes to the financial accounts and forms part of the Annual Report.
The policy on Related Party Transactions is part of the website of the Company. The web link for the policy on related party transaction is as under: https://www.rubramed.com/policies/Related-Party-Transaction.pdf
25. RISK MANAGEMENT
The Company has devised and implemented a mechanism for risk management.
26. FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTORS
The Company proactively keeps its Directors informed of the activities of the Company, its management and operations and provides an overall industry perspective as well as issues being faced by the industry. Details of the Familiarization program for Independent Directors form part of the website of the Company. The web link of Familiarization program is as under:
https://www.rubramed.com/policies/Familarisation-of-Independent-Director.pdf
27. MEETING OF BOARD OF DIRECTORS
The details of Board Meeting forms part of Corporate Governance Report.
28. CORPORATE GOVERNANCE
Pursuant to Regulation 15(2) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, compliance of Corporate Governance is not mandatory. However, the company has complied with the provisions of Regulation 17 to 27 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent possible. A separate section on Corporate Governance forms part of the Directors' Report as stipulated in Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, is included in the Annual Report as Annexure V.
29. MANAGEMENT DISCUSSION AND ANALYSIS REPORT
Management discussion and analysis report is annexed as Annexure VI.
30. STATEMENT OF COMPLIANCE OF APPLICABLE SECRETARIAL STANDARDS:
The Board hereby states that the Company has complied with all the applicable secretarial standards to the extent possible.
31. INDEPENDENT DIRECTOR'S MEETING
The Board of Directors of the Company meets once in every Financial Year without the presence of Executive Directors and Management of the Company. The role of the Directors is as per the provisions of Companies Act, 2013 as well as the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
32. DECLARATION BY INDEPENDENT DIRECTOR
Pursuant to Section 149(6) of the Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, the Independent Directors of the Company have given the declaration to the Company that they qualify the criteria of independence as required under the Act.
33. BOARD EVALUATION
Pursuant to the provisions of Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, the Board has carried out annual performance evaluation of its own performance, the directors individually as well the evaluation of the working of its Audit, Nomination & Remuneration and Stakeholder committee, including the Chairman of the Board who were evaluated on parameters such as level of engagement and contribution and independence of judgment thereby safeguarding the interest of the Company. The performance evaluation of the Independent Directors was carried out by the entire Board. The performance evaluation of the Chairman and the Non-Independent Directors was carried out by the
Independent Directors. The Directors expressed their satisfaction with the evaluation process.
34. PARTICULARS OF LOANS GIVEN, GUARANTEES GIVEN OR INVESTMENTS MADE UNDER SECTION 186 OF COMPANIES ACT, 2013
Particulars of loans, guarantees and investments made by Company pursuant to Section 186 of the Companies Act, 2013 are given in the notes to the financial accounts forming part of the Annual Report. The loans and advances made by the Company, during the financial year under review, are within the limits prescribed in the section 186 of the Companies Act, 2013.
35. MATERIAL CHANGES BETWEEN THE DATE OF THE BOARD REPORT AND END OF FINANCIAL YEAR
Subsequent to year under review, there was no change. As per MCA Circular, Current year AGM is being held through Video Conferencing. Necessary procedure is given in the AGM Notice. Members are requested to update their Email ID either by writing to the Company or through the Register or Transfer Agents.
36. MATERIAL DEVELOPMENTS DURING THE FINANCIAL YEAR
Material changes subsequent to the end of the financial year is disclosed herein above.
37. SIGNIFICANT AND / OR MATERIAL ORDERS PASSED BY THE REGULATORS
No significant and/or material order was passed by any Regulator, any Court in India or any Tribunal, impacting the going concern status and the Company's operations in future.
38. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR ALONGWITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR
As on March 31, 2024, there is no proceeding pending under the Insolvency and Bankruptcy Code, 2016.
39. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF
There is no one time settlement done with bank or any financial institution.
40. IN CASE THE SECURITIES ARE SUSPENDED FROM TRADING, THE DIRECTORS REPORT SHALL EXPLAIN THE REASON THEREOF
The trading of the company has not been suspended.
41. NOMINATION AND REMUNERATION POLICY
An extract of the Company's policy relating to directors appointment, payment of remuneration and discharge of their duties is annexed herewith. The web link to the Nomination and Remuneration Policy is as under:
https://www.rubramed.com/policies/NominationandRemunerationPolicy.pdf
42. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES
The Company does not have any employee/Director who is in receipt of remuneration exceeding the sum prescribed in Section 197 of the Companies Act, 2013 ("the Act") read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.
In terms of the provisions of Section 197(12) of the Act read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, a statement showing the names of the top ten employees in terms of remuneration drawn and names and other particulars of the employees drawing remuneration in excess of the limits set out in the said rules is available for inspection.
Having regard to the second proviso to rule 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, such particulars shall be made available to any shareholder on a specific request made by him in writing before the date of such Annual General Meeting. Any member interested in obtaining such information may write to the company. The same is annexed herewith as Annexure- III.
43. A STATEMENT REGARDING OPINION OF THE BOARD WITH REGARD TO INTEGRITY, EXPERTISE AND EXPERIENCE (INCLUDING THE PROFICIENCY) OF THE INDEPENDENT DIRECTORS APPOINTED DURING THE YEAR
In the opinion of the board, the independent directors fulfill the conditions specified in SEBI (LODR) Regulations, 2015, and are independent of the management of the Company. The Independent Directors have complied with the code prescribed in schedule IV of the Companies Act, 2013.
44. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013
The company has in place a policy for prevention of sexual harassment in accordance with the requirements of the Sexual Harassment of women at workplace (Prevention, Prohibition & Redressal) Act, 2013. Internal Complaints Committee has been set up to redress complaints received regarding sexual harassment. The Board thereafter constituted a sexual harassment committee where the chairperson of the Committee is Ms. Sneha Thakur, and Ms. Abha Kapoor and Mr. Gopal Sahu are the Members. All employees (permanent, contractual, temporary, trainees) are covered under this policy.
a. number of complaints filed during the financial year - None
b. number of complaints disposed of during the financial year - None
c. number of complaints pending as on end of the financial year - None
45. TRANSFER OF AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND
The Company does not have any funds lying unpaid or unclaimed for a period of seven years. Therefore, there were no funds which were required to be transferred to Investor Education and Protection Fund (IEPF).
46. ADEQUACY OF INTERNAL FINANCIAL CONTROLS
The Company has adequate internal financial controls besides timely statutory audit and limited reviews of performance taking place periodically.
47. REGISTRATION WITH INDEPENDENT DIRECTORS DATABANK
The Independent directors of the company are yet to be registered with Independent director databank.
48. DIRECTORS' RESPONSIBILITY STATEMENT
Pursuant to Section 134 of the Act, the Directors state that:
(a) In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;
(b) Appropriate accounting policies have been selected and applied consistently and have made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company as at March 31, 2024 and of the profit for the Company for the year ended March 31, 2024;
(c) Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
(d) The annual accounts have been prepared on a going concern basis;
(e) Proper internal financial controls were followed by the Company and such internal financial controls are adequate and were operating effectively;
(f) Proper systems are devised to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.
49. ACKNOWLEDGEMENT
Your Directors takes opportunity to show gratitude towards the assistance and cooperation received from Shareholders.
Abha Kapoor
Whole time Director and CFO
DIN:02799429